SPYRE THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $1.04M, a 373.06% increase year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $33.00K, a 25.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $146.00K, a 26.96% increase year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $219.00K, a 3.30% increase year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $1.45M, a 195.71% increase from fiscal 2020.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $490.00K, a 57.13% decline from fiscal 2019.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2019 was $1.14M, a 59.60% decline from fiscal 2018.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2018 was $2.83M, a 302.99% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-12-31 | $1.45M 10-K · filed 2023-03-02 | |
| 2021-09-30 | $1.04M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $33.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $146.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $490.00K 10-K · filed 2023-03-02 | |
| 2020-09-30 | $219.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $44.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $115.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $1.14M 10-K · filed 2022-03-08 | |
| 2019-09-30 | $212.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $46.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $261.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $2.83M 10-K · filed 2021-03-18 | |
| 2018-09-30 | $927.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $248.00K 10-Q · filed 2019-11-06 | |
| 2018-03-31 | $785.00K 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $702.00K 10-K · filed 2020-02-24 | |
| 2015-12-31 | $23.00K 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |